Anixa Biosciences (ANIX) Common Equity (2010 - 2026)

Anixa Biosciences (ANIX) has reported Common Equity for 17 consecutive years, with $14.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 2.89% year-over-year to $14.5 million; the trailing twelve-month figure through Apr 2026 stood at $14.5 million (down 2.89% YoY), and the FY2025 full-year result was $15.2 million, down 19.73% from the prior year.
• Common Equity declined to $14.5 million in Q2 2026 per ANIX's latest filing, from $15.2 million in the prior quarter.
• Across five years, Common Equity topped out at $33.2 million in Q1 2022 and bottomed at $14.5 million in Q2 2026.
• Historically, Common Equity has averaged $22.8 million across 5 years, with a median of $23.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 154.16% in 2022, then tumbled 33.99% in 2025.
• Over 5 years, Common Equity stood at $28.2 million in 2022, then dropped by 17.12% to $23.4 million in 2023, then slipped by 19.18% to $18.9 million in 2024, then declined by 19.73% to $15.2 million in 2025, then declined by 4.52% to $14.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $14.5 million, $15.2 million, and $16.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.